Literature DB >> 23492931

Neurodevelopmental and psychiatric issues in Down's syndrome: assessment and intervention.

Stefano Vicari1, Maria Pontillo, Marco Armando.   

Abstract

Down's syndrome (DS) is the most frequent genetic cause of intellectual disability and patients with DS show significant psychopathology (18-23%). Moreover, individuals with DS often show a cognitive decline associated with ageing characterized by a deterioration in memory, language and cognitive functioning. According to these relevant findings, an overview is presented of state-of-the-art knowledge of the neurocognitive, neurobiological and psychopathological profile, assessment and treatment of patients with DS. The linguistic characteristics of DS develop differently along distinct developmental trajectories. Thus, for example, morphosyntax deficit, especially in production, is more evident in adolescence than in early childhood and lexicon is usually better preserved in all ages (at least in comprehension). So far, rehabilitation is the only effective approach for improving cognitive and linguistic abilities. However, ongoing preliminary reports on other approaches such as transmagnetic stimulation or drugs suggest alternative or integrative treatment for the future. Individuals with DS show typical organization of brain structures related to some cognitive abilities, such as reduced volume in frontal and prefrontal areas, which is related to poor executive and linguistic abilities. They also frequently show psychiatric disorders such as externalizing disorders as well as depression, anxiety and obsessive-compulsive disorder. Nevertheless, as for other genetic syndrome with intellectual disability, there is a significant lack of research specifically focused on treatments of psychiatric and behavioural problems in DS. This is true both for psychosocial and for pharmacological interventions.

Entities:  

Mesh:

Year:  2013        PMID: 23492931     DOI: 10.1097/YPG.0b013e32835fe426

Source DB:  PubMed          Journal:  Psychiatr Genet        ISSN: 0955-8829            Impact factor:   2.458


  21 in total

1.  Factors associated with depression and anxiety in children with intellectual disabilities.

Authors:  D G Whitney; D N Shapiro; M D Peterson; S A Warschausky
Journal:  J Intellect Disabil Res       Date:  2018-12-26

2.  Changes in cognitive function after a 12-week exercise intervention in adults with Down syndrome.

Authors:  Lauren T Ptomey; Amanda N Szabo; Erik A Willis; Anna M Gorczyca; J Leon Greene; Jessica C Danon; Joseph E Donnelly
Journal:  Disabil Health J       Date:  2018-02-26       Impact factor: 2.554

3.  Longitudinal measures of cognition in the Ts65Dn mouse: Refining windows and defining modalities for therapeutic intervention in Down syndrome.

Authors:  J Luis Olmos-Serrano; William A Tyler; Howard J Cabral; Tarik F Haydar
Journal:  Exp Neurol       Date:  2016-02-24       Impact factor: 5.330

4.  Absence of Prenatal Forebrain Defects in the Dp(16)1Yey/+ Mouse Model of Down Syndrome.

Authors:  Joseph W Goodliffe; Jose Luis Olmos-Serrano; Nadine M Aziz; Jeroen L A Pennings; Faycal Guedj; Diana W Bianchi; Tarik F Haydar
Journal:  J Neurosci       Date:  2016-03-09       Impact factor: 6.167

Review 5.  Modelling the neurodevelopmental pathogenesis in neuropsychiatric disorders. Bioactive kynurenines and their analogues as neuroprotective agents-in celebration of 80th birthday of Professor Peter Riederer.

Authors:  Masaru Tanaka; Eleonóra Spekker; Ágnes Szabó; Helga Polyák; László Vécsei
Journal:  J Neural Transm (Vienna)       Date:  2022-05-28       Impact factor: 3.850

6.  Lifespan analysis of brain development, gene expression and behavioral phenotypes in the Ts1Cje, Ts65Dn and Dp(16)1/Yey mouse models of Down syndrome.

Authors:  Nadine M Aziz; Faycal Guedj; Jeroen L A Pennings; Jose Luis Olmos-Serrano; Ashley Siegel; Tarik F Haydar; Diana W Bianchi
Journal:  Dis Model Mech       Date:  2018-06-12       Impact factor: 5.758

Review 7.  Clinical aspects and biomarkers of Alzheimer's disease in Down syndrome.

Authors:  Panagiotis Zis; Andre Strydom
Journal:  Free Radic Biol Med       Date:  2017-09-01       Impact factor: 7.376

8.  Prevalence of Mental Health Conditions Among 6078 Individuals With Down Syndrome in the United States.

Authors:  Anne Rivelli; Veronica Fitzpatrick; Sagar Chaudhari; Laura Chicoine; Gengjie Jia; Andrey Rzhetsky; Brian Chicoine
Journal:  J Patient Cent Res Rev       Date:  2022-01-17

9.  Placebo Responses in Genetically Determined Intellectual Disability: A Meta-Analysis.

Authors:  Aurore Curie; Kathy Yang; Irving Kirsch; Randy L Gollub; Vincent des Portes; Ted J Kaptchuk; Karin B Jensen
Journal:  PLoS One       Date:  2015-07-30       Impact factor: 3.240

10.  Motor, linguistic, personal and social aspects of children with Down syndrome.

Authors:  Amanda Tragueta Ferreira-Vasques; Dionísia Aparecida Cusin Lamônica
Journal:  J Appl Oral Sci       Date:  2015 Jul-Aug       Impact factor: 2.698

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.